Johnson & Johnson shares surged approximately 3% to $270.19 Tuesday morning as investors rotated out of high-growth technology stocks and into defensive companies. The healthcare heavyweight reported second-quarter sales climbed 6.6% to $25.31 billion, while adjusted earnings reached $2.90 per share. Management also raised its 2026 outlook, targeting approximately $101.1 billion in revenue and $11.68 in adjusted earnings per share at the midpoint. The stock is trading at $271.19 versus an estimated fair value of $192.38, meaning it sits roughly 41% above its GF Value.
Johnson & JohnsonQ2 earnings beat and raised 2026 outlook
Compass Inc